Multicystic Mesotheliomas, Sarcomatoid Mesothelioma

In those patients diagnosed and treated early with a multimodality approach, including cytoreductive surgery and postoperative intraperitoneal hypothermic chemotherapy, a relatively long survival can be expected, with a median survival of 50-60 months.[69,70] This represents a significant advance due to mesothelioma treatment improvements.

As the incidence of MPM begins to decrease as asbestos exposure is eliminated, the prognosis for those diagnosed with mesothelioma will continue to improve.

Readers are encouraged to respond to the author at alex@omniazone.com or to Paul Blumenthal, MD, Deputy Editor of MedGenMed, for the editor's eyes only or for possible publication via email: pblumen@stanford.edu
Contributor Information
Alessio Bridda, Clinica Chirurgica I, Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, Via Giustiniani 2, Policlinico III Piano, 35128 Padova, Italy.
Ilaria Padoan, Department of Pathology, University of Padua, School of Medicine, Via Gabelli 61, 35128, Padova, Italy.
Roberto Mencarelli, Department of Pathology, University of Padua, School of Medicine, Via Gabelli 61, 35128, Padova, Italy.
Mauro Frego, Clinica Chirurgica I, Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, Via Giustiniani 2, Policlinico III Piano, 35128 Padova, Italy Author's Email: alex@omniazone.com.

References
1. Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging. 1985;24:293–328. [PubMed]
2. Cunha P, Luz Z, Seves I, et al. [Malignant peritoneal mesothelioma – diagnostic and therapeutic difficulties] Acta Med Port. 2002;15:383–386. [PubMed]
3. De Pangher Manzini V. Malignant peritoneal mesothelioma. Tumori. 2005;91:1–5. [PubMed]